Blueprint Medicines Corp (BPMC) Expected to Post Quarterly Sales of $3.19 Million

Equities research analysts expect Blueprint Medicines Corp (NASDAQ:BPMC) to announce $3.19 million in sales for the current quarter, according to Zacks Investment Research. Three analysts have provided estimates for Blueprint Medicines’ earnings. The lowest sales estimate is $1.13 million and the highest is $5.94 million. Blueprint Medicines reported sales of $5.89 million during the same quarter last year, which suggests a negative year-over-year growth rate of 45.8%. The firm is scheduled to issue its next quarterly earnings results on Wednesday, August 1st.

On average, analysts expect that Blueprint Medicines will report full-year sales of $7.20 million for the current financial year, with estimates ranging from $4.33 million to $8.77 million. For the next year, analysts expect that the firm will post sales of $8.51 million per share, with estimates ranging from $1.02 million to $20.00 million. Zacks Investment Research’s sales calculations are an average based on a survey of research analysts that that provide coverage for Blueprint Medicines.

Blueprint Medicines (NASDAQ:BPMC) last posted its quarterly earnings data on Wednesday, May 2nd. The biotechnology company reported ($1.29) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.06) by ($0.23). Blueprint Medicines had a negative net margin of 1,068.27% and a negative return on equity of 37.00%. The business had revenue of $0.95 million during the quarter, compared to analyst estimates of $2.82 million. During the same quarter last year, the business earned ($0.84) earnings per share. Blueprint Medicines’s revenue for the quarter was down 83.7% on a year-over-year basis.

Several research firms recently weighed in on BPMC. JMP Securities set a $109.00 target price on shares of Blueprint Medicines and gave the company a “buy” rating in a research note on Monday, April 16th. Wedbush raised their target price on shares of Blueprint Medicines from $98.00 to $106.00 and gave the company an “outperform” rating in a research note on Monday, April 16th. BidaskClub cut shares of Blueprint Medicines from a “strong-buy” rating to a “buy” rating in a research note on Thursday, March 29th. ValuEngine raised shares of Blueprint Medicines from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, May 2nd. Finally, Zacks Investment Research cut shares of Blueprint Medicines from a “hold” rating to a “sell” rating in a research report on Friday, February 23rd. One investment analyst has rated the stock with a sell rating, one has given a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the stock. The company presently has a consensus rating of “Buy” and an average target price of $87.20.

Shares of Blueprint Medicines traded down $2.79, hitting $67.00, during midday trading on Tuesday, Marketbeat Ratings reports. The stock had a trading volume of 16,787 shares, compared to its average volume of 593,964. Blueprint Medicines has a 12 month low of $41.41 and a 12 month high of $109.00. The company has a current ratio of 15.40, a quick ratio of 15.40 and a debt-to-equity ratio of 0.02. The stock has a market capitalization of $3.05 billion, a PE ratio of -17.80 and a beta of 1.02.

In other news, CEO Jeffrey W. Albers sold 20,000 shares of the business’s stock in a transaction dated Monday, May 7th. The shares were sold at an average price of $78.90, for a total value of $1,578,000.00. Following the completion of the sale, the chief executive officer now owns 20,000 shares of the company’s stock, valued at $1,578,000. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders own 3.15% of the company’s stock.

Several institutional investors have recently made changes to their positions in BPMC. Zurcher Kantonalbank Zurich Cantonalbank raised its stake in Blueprint Medicines by 57.3% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,866 shares of the biotechnology company’s stock valued at $141,000 after purchasing an additional 680 shares in the last quarter. Amalgamated Bank raised its stake in Blueprint Medicines by 16.9% in the fourth quarter. Amalgamated Bank now owns 5,777 shares of the biotechnology company’s stock valued at $436,000 after purchasing an additional 837 shares in the last quarter. UBS Asset Management Americas Inc. raised its stake in Blueprint Medicines by 1.0% in the fourth quarter. UBS Asset Management Americas Inc. now owns 109,788 shares of the biotechnology company’s stock valued at $8,279,000 after purchasing an additional 1,125 shares in the last quarter. Xact Kapitalforvaltning AB raised its stake in Blueprint Medicines by 39.0% in the first quarter. Xact Kapitalforvaltning AB now owns 5,351 shares of the biotechnology company’s stock valued at $491,000 after purchasing an additional 1,500 shares in the last quarter. Finally, Great West Life Assurance Co. Can raised its stake in Blueprint Medicines by 48.2% in the first quarter. Great West Life Assurance Co. Can now owns 4,937 shares of the biotechnology company’s stock valued at $453,000 after purchasing an additional 1,605 shares in the last quarter. 97.62% of the stock is owned by institutional investors.

Blueprint Medicines Company Profile

Blueprint Medicines Corporation, a biopharmaceutical company, develops drugs of small molecule kinase inhibitors that target genomic drivers in various cancers and a rare genetic disease. Its lead drug candidates include avapritinib, which is in Phase I clinical trials that targets KIT Exon 17 mutant proteins and PDGFRa D842V mutations, that are drivers of cancer and proliferative disorders, including gastrointestinal stromal tumors and systemic mastocytosis; and BLU-554, which is in Phase I clinical trials an orally available, potent, and irreversible inhibitor of the kinase FGFR4 that is activated in a defined subset of patients with hepatocellular carcinoma.

Get a free copy of the Zacks research report on Blueprint Medicines (BPMC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Blueprint Medicines (NASDAQ:BPMC)

Receive News & Ratings for Blueprint Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Blueprint Medicines and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply